Effect of the complementary administration of vitamin D in patients with postmenopausal osteoporosis without response to the treatment with antiresorptive therapy

Patricia Loranca-Moreno; Grisel Vázquez-Gallardo; María Belén Brito-Gavilanes; José Bacilio Hernández-Sánchez; Isela Vieyra-Lobato; Ana Yessica Chávez-León

2021, Number 4

<< Back Next >>

Med Int Mex 2021; 37 (4)

Effect of the complementary administration of vitamin D in patients with postmenopausal osteoporosis without response to the treatment with antiresorptive therapy

Loranca-Moreno P, Vázquez-Gallardo G, Brito-Gavilanes MB, Hernández-Sánchez JB, Vieyra-Lobato I, Chávez-León AY

Full text

How to cite this article

Language: Spanish
References: 35
Page: 529-539
PDF size: 297.32 Kb.

ABSTRACT

Background: Osteoporosis is a systemic bone disease in which there is low bone mass and a high risk of fracture that deteriorate the quality of life of postmenopausal patients, antiresorptive therapy, calcium and vitamin D are the main therapy.
Objective: To evaluate the efficacy of the complementary administration of vitamin D at doses of 4000 IU/day (Histofil^®) added to antiresorptive therapy (bisphosphonates vs denosumab) and calcium carbonate 1.2 g per day in patients with postmenopausal osteoporosis of Regional Hospital 1° de Octubre, ISSSTE, Mexico City.
Materials and Methods: Longitudinal and analytical experimental study carried out from January 2018 to July 2019 in patients with postmenopausal osteoporosis and antiresorptive therapy (bisphosphonates, denosumab or both), calcium carbonate plus vitamin D (Caltrate +D) for at least 12 months, 97.2% had hypovitaminosis D (concentrations lesser than 30 ng/dL), vitamin D 4000 IU (Histofil^®) was added for 12 months.
Resultados: One hundred and five patients were included. The results of bone mineral density were in the hip before supplementation and after, respectively: T score -1.90 ± 0.86 vs -1.50 ± 0.92; p = 0.003, while in the column T-score -2.70 ± 0.67 vs T-score -2.20 ± 1.55; p ≤ 0.001.
Conclusions: The administration and serum measurement of vitamin D (25-hydroxycholecalciferol) are highly relevant to assess the adequate response to the treatment of postmenopausal osteoporosis.

REFERENCES

GPC Diagnóstico y tratamiento de la Osteoporosis del Adulto NOM 083-38. http://www.nof.org/professionals/ hcp/clinicians-guide Actualizada en 2013.
Akkawi I, Merly HZ. Osteoporosis: Current Concepts. Joints 2018; 6: 122-127. https://doi.org/ 10.1055/s-0038- 1660790.
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update. Endocr Pract 2000; 26 (Suppl 1). doi. 10.4158/ GL-2020-0524SUPPL.
Shoback D, Rosen CJ, Black DM, Cheung AM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Guideline Update- J Clin Endocrinol Metab 2020; 105 (3): 1-8. doi. 10.1210/ clinem/dgaa048.
Rosas-Peralta M, Holick M, Borrayo-Sanchez G, Madrid- Miller A, et al. Dysfunctional immunometabolic effects of vitamin D deficiency, increased cardiometabolic risk. Potential epidemiological alert in America? Endocrinol Diabetes Nutr 2017; 64 (3): 162-173. doi. 10.1016/j.endinu. 2016.11.009.
Jodar G, González M, et al. Perspectivas actuales del papel de la vitamina D y del calcio en el cuidado del paciente con osteoporosis: Discusión de un panel de expertos. Rev de Osteoporos y Metab Miner 2010; 2: 65-75.
Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, et al. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone 2016; 91: 122-9. doi. 10.1016/j.bone.2016.07.019.
Dadoniene J, Čypienė A, Rinkūnienė E, Badariene J, et al. Vitamin D, cardiovascular and bone health in postmenopausal women with metabolic syndrome. Adv Clin Exp Med 2018 Jul 30. doi. 10.17219/acem/75147.
Schweitzer D, Amenábar PP, Botello E, López M, et al. Prevalencia de insuficiencia y deficiencia de vitamina D en adultos mayores con fractura de cadera en Chile Rev Med Chile 2016; 144: 175-180. doi. 10.4067/S0034- 98872016000200005.
Hall J. Hormona paratiroidea, calcitonina, metabolismo del calcio y del fosfato, vitamina D, huesos y dientes. En: Arthur C. Guyton. Tratado de fisiología médica. Philadelphia: McGraw-Hill Interamericana: 2001: 1081-99.
Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115 (12): 3318-3325. doi. 10.1172/JCI27071.
Camacho PM, Petak SM, Binkley N, Clarke BL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis— 2016. Endocr Pract 2016; 22 (suppl 4): S1-S42. doi. 10.4158/EP161435.GL.
Goessl C, Katz L, Dougall WC, Kostenuik PJ, et al. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci 2012; 1263: 29e40. http://dx.doi.org/10.1111/j.1749- 6632.2012.06674.x.
Van der Velde RY, Brouwers JR, Geusens PP, Lems WF, et al. Calcium and vitamin D supplementation: state of the art for daily practice. Food Nutr Res 2014; 7: 58. doi. 10.3402/ fnr.v58.21796.
Feldman D, Pike JW, Adams JS. Vitamin D. 3rd ed. San Diego: Elsevier; 2011: p. 1-2144.
Ominsky MS, Libanati C, Niu QT, Boyce RW, et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res 2015; 30 (7): 1280-1289. doi. 10.1002/jbmr.2480.
Seeman E, Delmas PD, Hanley DA, Sellmeyer D, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25: 1886-1894. doi. 10.1002/ jbmr.81.
Furuya Y, Inagaki A, Khan M, Mori K, et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kB ligand (RANKL)- binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem 2013; 288 (8): 5562-5571. doi. 10.1074/jbc.M112.426080.
Fan Y, Hanai JI, Le PT, Bi R, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab 2017; 25 (3): 661-672. doi. 10.1016/j.cmet.2017.01.001.
Faienza MF, Chiarito M, D’amato G, Colaianni G, et al. Monoclonal antibodies for treating osteoporosis. Expert Opin Biol Ther 2017; 18 (2): 149-157. doi. 10.1080/14712598.2018.1401607.
Bone HG, Bolognese MA, Yuen CK, Kendler DL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93 (6): 2149-57. doi. 10.1210/jc.2007-2814.
Bronwell L. The overlooked importance of vitamin D receptors. http://www.lef. org/magazine/2013/8/The- Overlooked-Importance-of-Vitamin-D-Receptors/ Page-01.
Anderson PH, Lam NN, Turner AG, Davey RA, et al. The pleiotropic effects of vitamin D in bone. J Steroid Biochem Mol Biol 2013; 136 (July): 190-4. http://dx.doi. org/10.1016/j.jsbmb.2012.08.008.
Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drug Aging 2007; 24 (12): 1017- 29. doi. 10.2165/00002512-200724120-00005.
Brincat M, Gambin J, Brincat M, Calleja-Agius J. The role of vitamin D in osteoporosis. Maturitas 2015; 80 (3): 329-332. doi. 10.1016/j.maturitas.2014.12.018.
Pepper KJ, Judd SE, Nanes MS, Tangpricha V. Evaluation of Vitamin D repletion regimens to correct Vitamin D status in adults. Endocr Pract 2009; 15 (2): 95-103. doi. 10.4158/ EP.15.2.95.
Lacey DL, Boyle WJ, Simonet WS, Kosteniuk PJ, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012; 11 (5): 401-419. doi. 10.1038/nrd3705.
Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone 2017; 96: 29-37. doi. 10.1016/j.bone.2016.10.007.
Kendler DL, Roux C, Benhamou CL, Brown JP, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25 (1): 72-81. doi. 10.1359/ jbmr.090716.
Brown JP, Prince RL, Deal C, Recker RR, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24 (1): 153-61. doi. 10.1359/ jbmr.0809010.
Lewiecki EM. Monoclonal antibodies for the treatment of osteoporosis. Expert Opin Biol Ther 2012; 13 (2): 183-196. doi:10.1517/14712598.2012.740006.
Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008; 88: 1519-27. DOI: 10.3945/ajcn.2008.26182.
Stein MS, Wark JD, Scherer SC, Walton SL, et al. Falls relate to vitamin D and parathyroid hormone in an Australian nursing home and hostel. J Am Geriatr Soc 1999; 47: 1195- 201. DOI: 10.1111/j.1532-5415.1999.tb05199.x.
Kalyani RR, Stein B, Valiyil R, Manno R, et al. Vitamin D treatment for the prevention of falls in older adults: systematic review and metaanalysis. J Am Geriatr Soc 2010; 58: 1299-310. DOI: 10.1111/j.1532-5415.2010.02949.x.
Michael YL, Whitlock EP, Lin JS, Fu R, et al. Primary carerelevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010; 153: 815-25. doi. 10.7326/0003-4819-153-12-201012210-00008.